Search hospitals
>
California
>
Los Angeles
USC / Norris Comprehensive Cancer Center
Claim this profile
Los Angeles, California 90033
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Colorectal Cancer
Conducts research for Prostate Cancer
960 reported clinical trials
64 medical researchers
Summary
USC / Norris Comprehensive Cancer Center is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and other specialties. USC / Norris Comprehensive Cancer Center is involved with conducting 960 clinical trials across 787 conditions. There are 64 research doctors associated with this hospital, such as Anthony El-Khoueiry, MD, Heinz-Josef Lenz, David Hong, MD, and Jacob Thomas, MD.
Area of expertise
Cancer
USC / Norris Comprehensive Cancer Center has run 309 trials for Cancer. Some of their research focus areas include:
Lung Cancer
USC / Norris Comprehensive Cancer Center has run 156 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Anthony El-Khoueiry, MD
USC Norris Comprehensive Cancer Center
3 years of reported clinical research
Heinz-Josef Lenz
USC / Norris Comprehensive Cancer Center
8 years of reported clinical research
David Hong, MD
M D Anderson Cancer Center
4 years of reported clinical research
Jacob Thomas, MD
USC Norris Comprehensive Cancer Center
2 years of reported clinical research
Clinical Trials running at USC / Norris Comprehensive Cancer Center
Cancer
Skin Cancer
Prostate Cancer
Lung Cancer
Bladder Cancer
Breast Cancer
Esophageal cancer
Colorectal Cancer
Kidney Cancer
Testicular cancer
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
Recruiting
2 awards
Phase 3
23 criteria
PF-07220060 + Letrozole
for Breast Cancer
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Recruiting
2 awards
Phase 3
4 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at USC / Norris Comprehensive Cancer Center?
USC / Norris Comprehensive Cancer Center is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and other specialties. USC / Norris Comprehensive Cancer Center is involved with conducting 960 clinical trials across 787 conditions. There are 64 research doctors associated with this hospital, such as Anthony El-Khoueiry, MD, Heinz-Josef Lenz, David Hong, MD, and Jacob Thomas, MD.
Where is USC / Norris Comprehensive Cancer Center located?
**USC Norris Comprehensive Cancer Center Location and Access:** - Address: 1441 Eastlake Ave, Los Angeles, CA 90033. - By Car: Accessible via I-10 W or I-110 S, exit at Exposition Blvd, proceed north on S Park View St, and turn right onto Elaine Ave. - Public Transportation: For routes and schedules, refer to Moovit for guidance from your specific location.
Who should I call to ask about financial aid or insurance network?
For financial assistance at USC Norris Comprehensive Cancer Center, contact the Business Office at (323) 865-3000 or email uscnorrisinfo@med.usc.edu. For insurance inquiries, use the same contact details. The Financial Assistance Program at Keck Medicine of USC, including USC Norris Hospital, is reachable at (855) 532-5729 or through their website for more details and forms.
What insurance does USC / Norris Comprehensive Cancer Center accept?
The USC Norris Comprehensive Cancer Center accepts a wide range of insurance plans, including but not limited to Aetna Healthcare, Anthem Blue Cross, Blue Shield of California, CIGNA, and United Healthcare. It's advised to verify benefits and network providers for specific products with your health plan, as not all providers participate in all health plan products or networks. The USC Trojan Care EPO and USC PPO plans specifically provide access to Keck Medicine of USC providers, including the USC Norris Comprehensive Cancer Center.
What awards or recognition has USC / Norris Comprehensive Cancer Center received?
The USC Norris Comprehensive Cancer Center, an NCI-designated comprehensive cancer center, is dedicated to reducing cancer health disparities in underserved communities, supported by a $25 million grant from The Ralph Lauren Corporate Foundation. It leads in cancer treatment and translates scientific discoveries into innovative therapies for patients.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.